Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no changes to study content, eligibility, or results are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:18:05.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now shows 'Results Submitted' in the results status area, and the previous 'No Results Posted' message has been removed.
    Difference
    0.1%
    Check dated 2026-01-06T17:00:46.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The Study Details page updated the Locations section, with state locations added and removed, and the page revision updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-23T09:14:41.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision from v3.2.0 to v3.3.2 appears to be a site-level update with no changes to the study details, eligibility criteria, or outcomes shown on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T17:03:56.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The government funding status banner was removed from the page. The study details, eligibility criteria, and related content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T15:06:07.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Added a requirement that participants consent to providing pre- and post-treatment tissue samples for future research. This affects eligibility and subsequent data collection for the study.
    Difference
    0.3%
    Check dated 2025-11-03T01:30:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.